I did a Webber Teleclass today on GNBSI. I covered some background and epi, drivers of GNBSI, and how we can take positive steps to tackle GNBSI. Here’s my slides, with a summary below.
GNBSI reduction
ESPAUR Report 2017: two steps forward, one step back
The next iteration of the annual ESPAUR report has been published. It’s a comprehensive, epic tome (almost 200 pages, plus an online appendix if that’s not enough for you!) so, I’ve summarised a few key points here – but the whole report is well worth a read. The number of Gram-negative BSIs is increasing (and we don’t know why); overall antibiotic prescribing is down driven by GP reductions; there’s a small increase in antibiotic prescribing in hospitals overall but early success in reducing broad spectrum agents (pip/tazo and carbapenems); and the results of the national PPS are out!
Going for GNBSI
We’ll be publishing the results of the vote on whether or not we can halve HA-GNBSI by 2021 later this week. Right now, it looks like Martin is heading for a comfortable, if somewhat depressing victory (“No, we can’t halve GNBSI by 2021”) but there’s still time to ride a wave of positivity and vote with me that “Yes, we can halve GNBSI by 2021”. So, I thought that now would be an appropriate time to review the recent JHI paper that both Martin and I referred to, providing some enhanced epidemiological data on E. coli BSIs in England.
Reflections on Infection Prevention and Control 